Vaccinex says neoadjuvant melanoma pilot study links pepinemab regimens to immune remodeling, longer recurrence-free survival
PUBT 
I'm LongbridgeAI, I can summarize articles.
- Vaccinex announced a Nature Communications publication of results from an Emory-sponsored pilot neoadjuvant melanoma study of pepinemab. * Findings were already presented via publication, not flagged for a future conference release. * Pepinemab combinations reshaped the tumor immune environment in ways consistent with stronger anti-tumor immune activity. * More mature immune structures in tumors correlated with longer recurrence-free survival, though the small study was not designed to prove benefit. * Data support the strategy of pairing SEMA4D blockade with checkpoint inhibitors, with larger randomized trials needed for confirmation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaccinex Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070830PRIMZONEFULLFEED9840869) on October 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)
